Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

S-Nitrosylation Therapy of COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04528771
Recruitment Status : Active, not recruiting
First Posted : August 27, 2020
Last Update Posted : October 21, 2021
Sponsor:
Collaborator:
Case Western Reserve University
Information provided by (Responsible Party):
Robert Schilz, University Hospitals Cleveland Medical Center

Brief Summary:
The primary objective of this study is to provide expanded access of S-nitrosylation therapy for the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV2) infection.

Condition or disease Intervention/treatment Phase
SARS-CoV2 Infection Covid19 Drug: SNO Drug: Nitrogen gas Early Phase 1

Detailed Description:
Randomized controlled trial for safety of a 6-hour escalating dose of S-nitrosylation therapy or placebo to ventilated patients. This will be a single-site study conducted within the UH-CMC medical ICU designated COVID-19 quarantine areas.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Single-site, double-blinded, randomized, placebo controlled trial with a superiority design. The study will randomize 24 patients 1:1 (12 treatment vs 12 control) to either S-nitrosylation therapy or placebo arms.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: The investigational product will be prepared and dispensed by designated unblinded site personnel at the pharmacy; the investigational product label will indicate the study number but will not indicate the treatment assignment. Any site personnel involved in the administration and assessment of the investigational product will be blinded to subject treatment assignments throughout the study.
Primary Purpose: Treatment
Official Title: Proof of Concept Safety Trial for S-Nitrosylation Therapy to Improve Oxygenation Status in Severe Covid-19 Patients Receiving Supplemental Oxygen Support
Actual Study Start Date : August 5, 2021
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : April 30, 2022

Arm Intervention/treatment
Experimental: SNO
12 patients in the S-nitrosylation arm will receive SNO (six-hour treatment with a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr).
Drug: SNO
Six-hour SNO treatment by inhalation at a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr. Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.

Placebo Comparator: Placebo
12 patients in the placebo arm will receive nitrogen gas (six-hour treatment).
Drug: Nitrogen gas
Six-hour nitrogen gas treatment by inhalation.Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
Other Name: Placebo




Primary Outcome Measures :
  1. Treatment Emergent Adverse Events [ Time Frame: 30 days ]
    Adverse events related to SNO therapy.

  2. Frequency of Intubation [ Time Frame: 30 days ]
    Number of intubations required.

  3. Progression to use of ECMO [ Time Frame: 30 days ]
    Use of ECMO required.


Secondary Outcome Measures :
  1. Time to Clinical Status Improvement [ Time Frame: 30 days ]

    Number of days required to see a greater than or equal to 2 point improvement on the WHO 9-point clinical status assessment ordinal scale.

    Clinical status will be assessed using the WHO 9-point ordinal scale as follows:

    0. Uninfected - no clinical or virological evidence of infection

    1. Ambulatory - no limitation of activities
    2. Ambulatory - Limitation of activities
    3. Hospitalized, mild disease - no oxygen therapy
    4. Hospitalized, mild disease - oxygen by mask or nasal prongs
    5. Hospitalized, severe disease - non-invasive ventilation or high-flow oxygen
    6. Hospitalized, severe disease - intubation and mechanical ventilation
    7. Hospitalized, severe disease - ventilation + additional organ support (pressors, RRT, ECMO)
    8. Dead

  2. Clinical Status [ Time Frame: 30 days ]

    Proportion of patients in each stage at maximum severity on the 9-point clinical status assessment ordinal scale.

    Clinical status will be assessed using the WHO 9-point ordinal scale as follows:

    0. Uninfected - no clinical or virological evidence of infection

    1. Ambulatory - no limitation of activities
    2. Ambulatory - Limitation of activities
    3. Hospitalized, mild disease - no oxygen therapy
    4. Hospitalized, mild disease - oxygen by mask or nasal prongs
    5. Hospitalized, severe disease - non-invasive ventilation or high-flow oxygen
    6. Hospitalized, severe disease - intubation and mechanical ventilation
    7. Hospitalized, severe disease - ventilation + additional organ support (pressors, RRT, ECMO)
    8. Dead

  3. Respiratory Clinical Status [ Time Frame: 30 days ]

    Respiratory clinical status assessed by a 7-point respiratory status ordinal scale that captures oxygen requirement, ventilator support or death.

    7-Point Respiratory Severity Scale Range: 1-7 Higher values = worse

    1. Not receiving oxygen supplementation; AND room air oxygen saturation ≥ 95%
    2. Supplemental oxygen ≤ 2 liters/min; OR room air oxygen saturation ≤ 94%
    3. Supplemental nasal oxygen >2 and <= 5 liters/min
    4. Supplemental nasal oxygen >5 liters/min
    5. HFNC or NIV with FiO2 > 50%
    6. Intubation or ECMO
    7. Death

  4. Duration of Hospitalization [ Time Frame: 30 days ]
    Duration of total hospitalization days as measured by total hospitalization, ventilator and ICU days

  5. All-Cause Mortality [ Time Frame: 30, 60 days ]
    All-cause mortality

  6. Time to Discontinuation of Oxygen Therapy [ Time Frame: 30 days ]
    Number of days required to discontinue oxygen supportive therapy

  7. Discontinuation of Oxygen Therapy [ Time Frame: 30 days ]
    Proportion of patients alive and with discontinued oxygen supportive therapy at day 30



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (Severe COVID-19 Status)

  • Hospitalized with confirmed SARS-CoV-2 infection by polymerase chain reaction (PCR) or other validated tests as they become available within 30 days of enrollment.
  • In mild respiratory distress, defined as a P/F ratio of between 200 and 325 mm Hg.
  • Spontaneously breathing subjects receiving > 4 liters/min of oxygen.
  • Patients enrolled and able to start ENO treatment after oxygen stabilization.
  • Willing and able to provide written informed consent, or with a legal representative who can provide informed consent, or enrolled under International Conference on Harmonization (ICH) E6(R2) 4.8.15 emergency use provisions as deemed necessary by the investigator (participants ≥ 18 years of age).
  • 18-89 years of age

Exclusion Criteria

  • COVID-19 patients with mild to no respiratory distress, defined as P/F ratio > 325 mm Hg.
  • COVID-19 patients receiving supplemental oxygen equivalent to an FiO2 of > 0.90 (reduction of FiO2 at this level or higher when ENO is blended into gas source cannot be avoided).
  • COVID-19 patients receiving supplemental oxygen with active ventilatory support, CPAP, etc.
  • Physician of record opposed to enrolling the patient due to perceived safety concerns; or any condition that does not allow the protocol to be followed safely.
  • Subjects with past medical history of lung malignancy or pneumonectomy or lung transplant
  • Subjects who have a history of malignancy or other irreversible disease/conditions with a 6-month mortality > 50%
  • Subjects that have experienced cardiac arrest with CPR for longer than 30 minutes
  • Patients on extracorporeal membrane oxygenation (ECMO) + patients intubated on ventilator
  • Patient groups at an increased risk to form methemoglobin. (e.g. congenital variants of Met-Hb)
  • Patients with anemia, defined as a hemoglobin of < 9 g/dL
  • Individuals who are pregnant or breastfeeding
  • Individuals with an acute disorder or history of chronic diseases of the heart, lungs, kidney, liver, or any other medical condition that in the opinion of the screening physician makes them unsuitable for study.
  • Individuals taking nitrates.
  • Individuals receiving PDE-5 inhibitors, any drugs that are nitric oxide donors (e.g. prilocaine, sodium nitroprusside and nitroglycerine), drugs known to increase methemoglobin (e.g. lidocaine, prilocaine, benzocaine, or dapsone), drugs that interfere with nitrite metabolism (e.g. allopurinol) and drugs that may potentiate hypotension (e.g. antihypertensives, diuretics, meperidine).
  • Individuals with an inherited or acquired blood coagulation disorder, congenital methemoglobinemia, or a familial hemoglobinopathy that impacts oxygen delivery (e.g. sickle cell).
  • Individuals who might have difficulty with the placement of a face mask (e.g. claustrophobia, uncontrolled asthma, severe allergies, sensitive skin) and/or the inhalation of a product for approximately 6 hours.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04528771


Locations
Layout table for location information
United States, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
Sponsors and Collaborators
Robert Schilz
Case Western Reserve University
Investigators
Layout table for investigator information
Principal Investigator: Robert Schilz, DO, PhD University Hospitals Cleveland Medical Center
Layout table for additonal information
Responsible Party: Robert Schilz, Principal Investigator, University Hospitals Cleveland Medical Center
ClinicalTrials.gov Identifier: NCT04528771    
Other Study ID Numbers: STUDY20210599
First Posted: August 27, 2020    Key Record Dates
Last Update Posted: October 21, 2021
Last Verified: October 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Robert Schilz, University Hospitals Cleveland Medical Center:
respiratory distress
respiratory failure
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases